The Only End-To-End Plasmid-Free DNA Platform For Cleaner, More Controlled Starting Material

Advances in synthetic DNA are reshaping how genetic medicines are designed, produced, and delivered across a growing range of therapeutic applications. By moving beyond traditional plasmid-based approaches, optimized DNA constructs offer improved stability, higher expression levels, and more efficient transcription, all of which are critical for next-generation therapies. These engineered DNA formats can be scaled from microgram to gram quantities using streamlined production methods, enabling greater flexibility for both research and clinical manufacturing. Customizable adapter designs also allow developers to fine-tune delivery performance, enhance release from vectors, and tailor immune responses to specific therapeutic goals. As a result, optimized DNA supports a wide spectrum of applications, including viral and non-viral gene therapies, gene editing, and both DNA- and RNA-based vaccines, helping drive more precise and effective treatments.